News Articles 31 - 40 of 160

04
Nov
British Liver Trust: Launch of Liver Cancer UK as cases of the disease rise dramatically across the country
News Type: BASL News

On 27th October 2022 the British Liver Trust launched Liver Cancer UK in response to rising cases of liver cancer across the country.

Liver cancer is the fastest rising cause of cancer death in the UK. Over the past decade, liver cancer incidence rates have increased by almost half (45%) in the UK and the number of people dying from liver cancer has risen the fastest out of all the twenty most common types of cancer. There are now over 40% more deaths from liver cancer in both men and women than there were a decade ago (1&2).

The disease also has a high mortality rate. Every year over 6,000 people are diagnosed with liver cancer country-wide and just 13% of them will survive for five years or more. (3) Survival rates depend on several factors, including the stage of the disease when it is diagnosed.

Many patients with liver cancer will only be diagnosed after an emergency admission to hospital or an emergency GP referral after symptoms have become severe and the cancer is more advanced. (4) In England, 44.9% of liver cancers are diagnosed in an emergency setting, such as an A&E department (5).

Liver Cancer UK will provide much needed information and support for patients affected by this devastating cancer and provide a focus for action to address this escalating situation. It will aim to improve the lives and outcomes of people affected by liver cancer and, ultimately, reduce cases of the disease.

The British Liver Trust will continue to work towards a world free of all liver diseases in addition, and as part of, its commitment to tackle liver cancer. Liver cancer is most common in people who already have liver disease, especially if they have cirrhosis (damage and scarring) of the liver which is most often caused by viral hepatitis, alcohol or obesity (6).

Pamela Healy OBE, Chief Executive of British Liver Trust, said:
“Liver cancer patients have told us that they didn’t realise that the British Liver Trust was also here for liver cancer patients - they were often confused and worried and did not know where to turn for help. We’ve created new resources and a website with targeted information to make it easier for people to get the help they need. The new programme of activity is in response to the very worrying increase in cases across the UK. We’re also deeply concerned that survival rates for liver cancer remain so low. It’s a situation which needs to urgently change.

“Liver Cancer UK, as part of the British Liver Trust, will be dedicated to saving and improving the lives of people affected by liver cancer by raising awareness, providing support and campaigning for faster diagnosis and more research into treatments and cures.”

Fiona Bailey (age 48), a liver cancer patient from Hampshire, said:
“When I was diagnosed with liver cancer, aged 45, my husband and I weren’t sure where to turn for support. At the time, I didn’t know anybody who had gone through it apart from my father-in-law who was diagnosed ten years earlier. I was diagnosed in time for surgery although I do continue to live with the ‘worry’ that it could come back. It’s brilliant that the British Liver Trust is launching Liver Cancer UK to provide dedicated information and support to patients like me and to increase awareness of liver cancer to ensure more people are diagnosed earlier. When you’ve been through something like this you just want to help other people.”

As well as the rising cases, late diagnosis of liver cancer continues to be a problem. This is partly due to the population’s low awareness of the symptoms of the disease. In 2021, the Less Survivable Cancers Taskforce released data showing that only 5% of people in the UK were able to correctly identify all symptoms of liver cancer from a list presented to them.

Professor Stephen Ryder, Medical Advisor to the British Liver Trust and Consultant Hepatologist at NHS Nottingham University Hospital, added:

“Lack of awareness of primary liver cancer and its causes is a common problem in the UK.

“The causes of liver disease and HCC, the most common primary liver cancer, are similar and interlinked. The good news is that there are things you can do to reduce the risks. Maintaining a healthy weight, avoiding drinking alcohol excessively and protecting yourself against viral hepatitis are the best defences against both liver disease and liver cancer.

“People can also develop cancer of the liver and gallbladder without the associated risk factors and should be concerned if they have any symptoms that are persistent and not normal for them. If you’re experiencing symptoms such as loss of appetite, nausea, a swollen stomach or yellowing of your skin and/or eyes, please don’t ignore them - make an appointment with your doctor to get them checked out.”

Symptoms of liver cancer include unintentional weight loss, loss of appetite, feeling very full after eating, feeling and being sick, pain or swelling in your abdomen, jaundice (yellowing of your skin and the whites of your eyes), itchy skin, feeling very tired and weak, fever with shivers, vomiting blood, dark black tarry poo or dark urine. However, the majority of these symptoms do not occur until liver cancer is at an advanced stage, so the British Liver Trust is calling for all people who are diagnosed with cirrhosis and who are most at risk to be regularly screened for liver cancer.

Visit Liver Cancer UK to find out more.


1.Over the last decade, liver cancer incidence rates have increased by almost half (45%) in the UK. Rates in females have increased by almost two-fifths (38%), and rates in males have increased by almost half (46%) (2016-2018): https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/liver-cancer#heading-Zero 
2.Liver cancer has shown the fastest increase in mortality (within the current 20 most common UK causes of cancer death) over the past decade in the UK for both females and males. Liver cancer mortality rates have increased by 45% in females and 42% in males over the past decade in the UK. Reference: Cancer Research UK (2019). Cancer mortality for common cancers. [online]. Available at: https://www.cancerresearchuk.org/health-professional/cancer-statistics/mortality/common-cancers-compared (last accessed October 2022).
3.https://britishlivertrust.org.uk/liver-cancer-awareness-month/ 
4.The Emergency Presentation Route comprises different emergency pathways into secondary care, including A&E attendance, emergency GP referrals to an inpatient setting (non–two week wait referrals) and emergency admissions to either an inpatient or outpatient setting.
5. https://www.cancerdata.nhs.uk/emergencypresentations . Data compared for 2020 Q3. Percentages differ slightly when compared to the National Cancer Registration Dataset due to diagnostic coding - this data is only currently available for 2006-2016.
6.https://britishlivertrust.org.uk/information-and-support/living-with-a-liver-condition/liver-conditions/liver-cancer-hcc/ 


 

03
Nov
Opportunity to Join the BASL Committee – Nominations are open for BASL Committee BVHG Chair & BVHG Secretary Posts
News Type: BASL News

Get Involved - and serve on the BASL committee and help to shape the future of BASL.

The British Viral Hepatitis Group (BVHG) Chair and BVHG Secretary posts are coming to the end of tenure.

The BVHG aims to improve the management and study of patients with chronic viral liver disease, bringing together UK hepatologists, gastroenterologists, infectious disease physicians, virologists and interested epidemiologists.

The Chair sits on the BASL Governing Board and is responsible for the organisation of educational events and is supported in the running and administrative tasks by the Secretary.

Both the BVHG Chair and BVHG Secretary posts are elected by the BASL membership to serve for a period of up to three years.

The BVHG is commissioned by the Governing Board to:
• a) promote research and the exchange of scientific information concerning viral hepatitis;
• b) foster multicentre scientific studies pertaining to viral hepatitis within the UK;
• c) promote education of physicians, surgeons, clinical nurse specialists and scientists
• with regard to viral hepatitides and their management;
• d) Promote interaction between clinical disciplines to promote good care of patients and foster research and clinical trials.

* The Chair post shall be registered with Companies House as a Director of BASL and registered with the Charities Commission as a Trustee.

BASL is committed to promoting equality, diversity and inclusion in all aspects of its work. It is actively promoting equal opportunities and access for all our members regardless of their background. We would, therefore, encourage you to consider joining the BASL committee to help to shape the future of BASL and increase our inclusivity/inclusiveness.

Nomination Process
Please send your nominations stating the position that the nomination is for to the BASL Secretariat at judy@basl.org.uk  by the deadline of 09:00hrs Friday 18th November 2022.

Candidates wishing to be considered for nomination must be a member of BASL and will require one BASL member to propose them and a second BASL member to confirm their suitability for the role in writing. (Proposing and seconding of candidates can be done by email.)

If more than one candidate is nominated for a post the Secretariat will arrange for an election of all members. Should an election need to take place the Secretariat will contact the candidates and request a personal statement. The statement should contain no more than 300 words and permission will be requested to share the personal statements with the BASL membership. (Personal statements are intended for this purpose only.)

The successful candidate will be elected by a simple majority of those members voting.

If you need any more information, please do not hesitate to contact judy@basl.org.uk .

We look forward to hearing from you.

(Originally added 27 October)

07
Sep
BASL & BSG NAFLD SIG launches first British audit of care of people with fatty liver disease
News Type: BASL News

We are conducting a national retrospective audit to identify practice of outpatient NAFLD management according to national quality standards/international guidelines and explore the changes in NAFLD outpatient services over the last 3 years across the UK. This will require registration as an audit with the local clinical audit department and a search of new patients reviewed in outpatient Gastroenterology and Hepatology clinics with suspected or confirmed diagnosis of NAFLD in March 2019 and March 2022.

No centre or patient-identifiable data will be included in any results disseminated. A nominated Gastroenterology or Hepatology consultant will receive a report of local results, with reference to the national findings at a later date for future auditing purposes.

If you would like to get involved, please access the documents below and follow the necessary steps:

Instruction letter including link to survey:
Download 2 - NAFLD audit_instruction letter for data collection.pdf

Audit registration form:
Download NAFLD audit_audit registration form.pdf

An audit registration form can be obtained by emailing paula@basl.org.uk or wenhao.li@nhs.net .

Please submit all collected data by 30th September 2022 - deadline has been extended from 31st August 2022.

If there are further questions regarding this project, we would be more than happy to answer them and you can contact us by emailing wenhao.li@nhs.net .

16
Aug
Opportunity - RCP Editor-in-Chief, Medical Care - driving change
News Type: BASL News

The Royal College of Physicians (RCP) is inviting applicants for the post of editor-in-chief, Medical Care - driving change. 

The RCP is leading in the development and delivery of a modern, engaging, and relevant portal to support clinical teams to deliver long-lasting improvements in care. Medical Care - driving change will deliver against the RCP’s strategic aim to improve health and healthcare.

The editor-in-chief will advise, review, and approve all aspects of web content for Medical Care - driving changes that are proposed by content advisors.

Content advisors will highlight suitable content produced by key partners and stakeholders and contribute their original content through a wide range of communication tools such as podcasts, webinars, blogs and longer reads.

The editor-in-chief will ensure content is aligned to the content themes agreed by the content board and aligned to the RCP strategic aims, using insight and good judgement to inform decision-making. Supported by the RCP’s communication and editing team and programme team, the editor-in-chief will ensure that ethical publishing standards are always adhered to, and that content is vibrant, diverse, and inclusive.

To apply or find out more visit the RCP website > Here .

Applications deadline - 2 September 2022.  Successful candidates notified 5-9 September 2022.  Interviews mid-late September 2022. 

08
Jul
Clinical recommendations for pre-treatment assessment of people preparing to initiate therapy for chronic hepatitis C infection
News Type: BASL News

Download Clinical recommendations for pre-treatment assessment of people preparing to initiate therapy for chronic hepC infection.pdf

Please contact Professor Foster directly by email g.r.foster@qmul.ac.uk if you have any questions. 

07
Jul
Dame Sheila Sherlock Research Prize 2022 - Applications Open
News Type: BASL News

Each year BASL presents the Dame Sheila Sherlock research prize, one of the highlights of the annual meeting. This prize is awarded annually to recognise the enormous contribution of Dame Sheila Sherlock to the development of Hepatology as a discipline in its own right.

Dame Sheila was involved in the foundation of the British Liver Club in 1961, which subsequently evolved into The British Association for the Study of the Liver (BASL). She was one of our past presidents and the first recipient of The BASL Distinguished Service Award.

Eligibility
In keeping with Dame Sheila’s enthusiasm for fostering young researchers, this eponymous research prize is awarded to young investigators without substantive posts in either medicine or science for their research contributions in the field of hepatology. The winner will receive free registration to the meeting, an award and a prize of £1,000 and an invite to deliver the prize lecture and present their research at the BASL Annual Meeting.

To apply, please send one A4 sheet outlining your research and another A4 sheet listing up to 5 related publications.

Please send submissions to steve@basl.org.uk before the deadline of Midday on Monday 1st August 2022.

You must be a BASL member to apply.


The BASL Annual Meeting Is taking place from 20th-23rd September at the Queen's Hotel in Leeds - Early Bird registration closes 31st July. Read more about registering > here .

07
Jul
Andy Burroughs Young Investigator Award - Applications Open
News Type: BASL News

The Andy Burroughs Young Investigator Award was set up in honour of the late Professor Andrew Burroughs.

Professor Burroughs was an eminent and world renowned Professor of Hepatology and Consultant Physician/Hepatologist and among his many achievements including his wide area of expertise in cirrhosis and portal hypertension and significant contribution to liver Transplantation.

Eligibility
This prize is awarded to young investigators who have contributed to clinical or translational research related to liver disorders who are in training or within 2 years of taking up consultant positions (or equivalent); this year the winner will receive free registration to the meeting, an award and a prize of £1,000 and an invite to deliver the prize lecture and present their research at the British Liver Transplant Group (BLTG) Annual Meeting in Leeds on Tuesday 20th September.

To apply, please send one A4 sheet outlining the research and another A4 sheet listing up to 5 related publications.

Please send submissions to steve@basl.org.uk before the deadline of Midday on Monday 1st August 2022.

You must be a BASL member to apply.


The BLTG Annual Meeting is part of the BASL Annual Meeting that is taking place from 20th-23rd September at the Queen's Hotel in Leeds - Early Bird registration closes 31st July.  Read more about registering > here .  

04
Jul
Opportunities to Join the BASL Committee - Expressions of Interest and Nominations – deadline 09:00hrs Tuesday 19th July 2022
News Type: BASL News

There are a number of opportunities coming up for members to serve on the BASL committee so please get involved and help to shape the future of BASL.

Detailed below are the elected committee posts that are coming to the end of tenure in September 2022:

President Elect - elected by the membership. The President is one of three principal officers of the Association. The post holder will shadow the BASL President from October 2022, taking up the role of President at the end of the Business Meeting of the Association in September 2023. The President is the Chairman of the Association and serves for two years. The President will Chair the annual Scientific Meeting and the meetings of the Governing Board.

Treasurer – elected by the membership. The Treasurer is one of three principal officers of the Association. The post holder can serve for up to three years and may be re-elected once.
Read more about this post here:
Download BASL Committee Posts_Information June 22.pdf

NB: The President, Secretary and Treasurer post holders must have different Institutional affiliation within the UK.

Education & Training Committee Councillor – elected by the membership. The post holder will serve for a period of four years and may be re-elected once. There are two Educational and Training Councillor’s on the Governing Board and members elect one new Councillor every two years. The post holders are responsible for educational tasks as defined by the Governing Board, such as running the BASL School of Hepatology.

BLTG Chair - elected by the membership. The post holder will serve for a period of up to three years and may be re-elected once.
Read more about this post here:
Download BASL Committee Posts_Information June 22.pdf

• BLNA Chair - elected by membership. The post holder will serve for a period of up to three years and may be re-elected once. The BLNA is commissioned by the Governing Board to promote education of nurses with regard to liver diseases and their management.

Services Lead - elected by the membership. The post holder will serve for a period of up to three years and may be re-elected once. The Services Lead supports the development and implementation of Clinical Standards and the provision of Clinical Services, including preparation and delivery of advice to national health authorities concerning liver diseases.
Read more about this post here:
Download BASL Committee Posts_Information June 22.pdf

Scientist Representative - elected by the membership. The postholder will serve for a period of up to three years and may be re-elected once. The post holder is responsible for the organisation and programme for the annual Basic Science Retreat meeting.

NB: all of the above posts, with the exception of President Elect, shall be registered with Companies House in the UK as a Director of BASL and registered with the Charities Commission as a Trustee.

BASL is committed to promoting equality, diversity and inclusion in all aspects of its work. It is actively promoting equal opportunities and access for all our members regardless of their background. We would, therefore, encourage you to consider joining the BASL committee to help to shape the future of BASL and increase our inclusivity/inclusiveness.


Nomination Process

Please send your nominations, clearly stating the position that your nomination is for, to the BASL Secretariat at judy@basl.org.uk by the deadline of 09:00hrs Tuesday 19th July 2022.

Candidates wishing to be considered for nomination must be a member of BASL and will require one BASL member to propose them and a second BASL member to confirm their suitability for the role in writing. (Proposing and seconding of candidates can be done by email.)

If more than one candidate is nominated for a particular post the Secretariat will arrange for an election of all members. Should an election need to take place the Secretariat will contact the candidates and request a personal statement. The statement should contain no more than 300 words and permission will be requested to share the personal statements with the BASL membership. (Personal statements are intended for this purpose only.)

The successful candidate will be elected by a simple majority of those members voting.

Newly elected committee members will be announced at the next Business Meeting of the Association that is being held during the BASL Annual Meeting in Leeds from 20th- 23rd September 2022, and join the committee thereafter.

If you need any more information, please do not hesitate to contact judy@basl.org.uk .

We look forward to hearing from you.

29
Jun
Gilead Fellowship Grants Programme: Viral Hepatitis
News Type: BASL News

The Gilead UK & Ireland 2022 Viral Hepatitis Fellowship Grants Programme is now accepting applications for funding. The Fellowship Programme is a medical grants funding stream that helps drive innovative diagnostic/care models and supports best practice sharing initiatives amongst healthcare professionals. Since 2008, the programme has supported over 300 projects within several therapy areas. Its ultimate aim is to help improve the lives of patients, in the field of viral hepatitis, with a focus on hepatitis delta virus (HDV).

This year, they are inviting applications from healthcare (e.g., clinicians, nurses, pharmacists) or allied (e.g., clinical researchers, laboratory technicians) professionals for proposals that evaluate existing, or implement and evaluate new, innovative initiatives focused on increasing appropriate HDV testing alone or in combination with hepatitis B, with subsequent liver management. 

Priority will be given to those projects that focus on the optimisation of the pathways for the diagnosis and management of HDV. Gilead particularly welcomes any project that demonstrates replicable and scalable potential.

Projects that fall outside of this scope, but which will add clinical value, or which investigate an area of unmet need in the field of HDV can also be submitted. All applications will be reviewed and appraised based on their individual merit and focus on driving positive change in patient care.

Please note that any applications which generate specific patient clinical outcomes (either classified as interventional or non-interventional studies according to EUDRACT criteria) cannot be accepted. These fall under the category of a clinical trial and, as such, will be considered out of scope of the Fellowship Programme.

The application window will close on Saturday 6th August 2022. If you have a project which you think may be relevant, Gilead encourages you to learn if your project is eligible and apply here.

Should you have any general enquiries or questions regarding the process, application form, or your project eligibility, please email gileadfellowship@axon-com.com who will be happy to support you with your request.

 

08
Jun
Trainee member of the CRN: Hepatology National Specialty Group
News Type: BASL News

Applications are invited from any UK Hepatology SpR to be the Trainee representative on the Hepatology National Specialty Group of the NIHR Clinical Research Network (CRN) for a term of two years.

This is an excellent opportunity to learn about clinical trials feasibility and delivery, as well as gain valuable experience in research leadership. The Trainee will join the 15 Local CRN (LCRN) Leads on the Group and will work with/obtain mentorship from the LCRN Lead for his/her geographic region of work. Prior experience/involvement in clinical studies on the UKCRN Portfolio is desirable, as is a desire to work in the future as a Principal Investigator and potentially take on a role in the CRN. The Trainee member will also be expected to take an interest in one of the Group's themes (Industry studies, patient and public involvement [PPI], Communications).

Applications should take the form of a research CV and a maximum 200 word description of the reason(s) for applying and expected individual gains.

Please send applications and queries to crnspecialtyclustera@nihr.ac.uk by 5pm Friday 8th July 2022.